-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

2seventy bio Announces Expanded Translational Collaboration With Regeneron To Develop New Cell Therapy-Based Combinations Dor Solid Tumors; Regeneron To Invest $20M In 2seventy Equity

Benzinga · 01/06/2023 09:12

Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches

Regeneron Investing $20 million in 2seventy Equity; Regeneron to Fund 100% of Clinical Development Costs for Regeneron-Based Combination Clinical Trial Arms Through Approval